COL18A1 and non-small cell lung carcinoma: No prolonged OS was seen in a real-world study of the efficacy of chemotherapy combined with recombinant human endostatin following 7-day continuous infusion and 14-day intravenous infusion in 54 patients with NSCLC (p = 0.111) (32).